Skip to content

Study · Non-randomized trial · 2013

1 result

Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans.

Hu W, Li L, Yang M, Luo X, Ran W, Liu D, Xiong Z, Liu H, Yang G

The Journal of clinical endocrinology and metabolism26 Nov 2012Cited by 100 (Europe PMC)

PMID23185036 (opens in a new tab)DOI10.1210/jc.2012-2466 (opens in a new tab)PepBankPUB-23185036
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialMechanism

    In humans, liraglutide increased circulating Sfrp5 levels, whereas hyperglycemia decreased them.

    In plain wordsIn people, liraglutide raised blood levels of the protein Sfrp5, while high blood sugar lowered them.

    Peptide
    Liraglutide
    Outcome
    IncreaseCirculating Sfrp5 level after liraglutide
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hyperglycemia decreased circulating Sfrp5 levels, whereas liraglutide increased Sfrp5 levels.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.